공간 오믹스(OMICS) 시장 : 기술, 제품, 용도, 워크플로우, 샘플 유형, 최종 용도별- 세계 예측(2024-2032년)

Global Spatial OMICS Market size is expected to exhibit 14.3% CAGR from 2024 to 2032, due to the increasing number of collaborations and partnerships. Of late, researchers and companies are actively joining forces to develop advanced imaging techniques and computational tools. These initiatives are focused on uncovering new insights into cellular interactions and tissue architecture. Moreover, such partnerships will continue to evolve for integrating AI and machine learning to analyze complex datasets more efficiently.

The increasing advancements for enhancing spatial resolution capabilities and expanding applications in disease research, personalized medicine, and drug discovery for shaping the future of biomedical sciences will drive the industry growth. For instance, in March 2024, Firalis Molecular Precision (FMP) partnered with Vizgen to launch a Grant Program for European researchers. This initiative helped to advance spatial omics technology for enhancing the understanding of biological systems at the cellular level through innovative research projects.

The spatial OMICS market is segregated into technology, product, application, workflow, sample type, end-use, and region.

By product, the instruments segment is estimated to rise at significant rate from 2024 to 2032, due to their ability to provide high-resolution and spatially resolved data on cellular and tissue architecture. Researchers are using advanced imaging systems and molecular profiling tools to map gene and protein expressions within their spatial context. In addition, continuous improvements are enhancing instrument sensitivity, speed, and data integration capabilities. Recent advancements are also making way for more precise analysis of complex biological systems in drug discovery, disease research, and personalized medicine.

Spatial OMICS industry from the pharmaceutical and biotechnology end-use segment is expected to expand from 2024 to 2032. Of late, pharmaceutical and biotechnology companies are integrating spatial omics technology to advance drug discovery and development processes. They are leveraging spatially resolved data to understand complex biological mechanisms and disease pathways more comprehensively. Moreover, these firms are increasingly collaborating with academic institutions and technology providers to refine analytical techniques and computational tools.

Regionally, the Europe spatial OMICS industry size is projected to depict robust growth between 2024 and 2032, propelled by the rising healthcare expenditure and the ongoing focus on drug discovery and development. Governments and private sectors in the region are investing in advanced technologies to enhance biomedical research and improve healthcare outcomes. Additionally, increasing developments for integrating spatial OMICS for enhancing data analysis capabilities as well as fostering collaborations between research institutions and pharmaceutical companies to drive breakthroughs in disease understanding and treatment will favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in omics technologies
    • 3.2.1.2 Increasing applications in personalized medicine
    • 3.2.1.3 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments and data storage
    • 3.2.2.2 Complex regulatory requirements and standardization issues
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Spatial transcriptomics
• 5.3 Spatial genomics
• 5.4 Spatial proteomics

Chapter 6 Market Estimates and Forecast, By Products, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Instruments
  • 6.2.1 By Mode
    • 6.2.1.1 Automated
    • 6.2.1.2 Semi-automated
    • 6.2.1.3 Manual
  • 6.2.2 By Type
    • 6.2.2.1 Sequencing platforms
    • 6.2.2.2 IHC
    • 6.2.2.3 Microscopy
    • 6.2.2.4 Flow cytometry
    • 6.2.2.5 Mass spectrometry
    • 6.2.2.6 Other types
• 6.3 Consumables
• 6.4 Software
  • 6.4.1 Bioinformatics tools
  • 6.4.2 Imaging tools
  • 6.4.3 Storage & management databases

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Diagnostics
• 7.3 Translation research
• 7.4 Drug discovery and development
• 7.5 Single cell analysis
• 7.6 Cell biology
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Workflow, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Sample preparation
• 8.3 Instrumental analysis
• 8.4 Data analysis

Chapter 9 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Formalin-Fixed Paraffin-Embedded (FFPE)
• 9.3 Fresh frozen

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Academic & research institutes
• 10.3 Pharmaceutical and biotechnology companies
• 10.4 Contract research organizations
• 10.5 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 10x Genomics
• 12.2 Akoya Biosciences, Inc.
• 12.3 Bio-Techne Corporation
• 12.4 BioSpyder, Inc.
• 12.5 Bruker Corporation
• 12.6 Danaher Corporation
• 12.7 Diagenode Diagnostics (Hologic, Inc.)
• 12.8 Ionpath, Inc.
• 12.9 Millennium Science Pty Ltd.
• 12.10 NanoString Technologies, Inc.
• 12.11 PerkinElmer, Inc.
• 12.12 S2 Genomics, Inc.